It has been demonstrated that, in transplanted cancer patients, the PD-L1/2-silenced DCs pulsed with minor histocompatibility antigen (MiHA) mRNA exhibit an improved stimulatory capability and amplified ex vivo antigen-specific CD8+ T cell immunity [44]. The gene discussed is XIAP; the disease is cancer.